Skip to main content
APhA 2024 Annual Meeting and Exposition Main banner
Final Program


Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Back
ViewAttendees 3

Advanced Clinical

Community Pharmacy

Health System Pharmacy

We’re Not in Enoxaparin Anymore: Anticoagulation in Cancer

Sunday, March 24, 2024
7:45 AM – 8:45 AM East Coast USA Time
Location: Orange County Convention Center, W311EF
CE: 1.0

ACPE Number: 0202-0000-24-092-L01-P

Number of Hours: 1

Activity Type: Application

Disclosure(s):
Lisa Cordes, PharmD, BCACP, BCOP: No financial relationships to disclose
In patients with cancer, venous thromboembolism (VTE) is the second leading cause of death after disease progression. Historically, low-molecular-weight heparins have been the standard of care in ambulatory patients with cancer associated VTE, however recent guidelines and evidence have suggested a shift to direct oral anticoagulants. Attend this session to hear from an expert in the field about updates related to anticoagulation in cancer.  

Learning Objectives:

  • Analyze clinical practice guideline recommendations for anticoagulation in patients with cancer.  
  • Evaluate the evidence related to anticoagulant use in patients with cancer. 
  • Discuss safety considerations associated with anticoagulant use in patients with cancer. 
  • Select the most appropriate anticoagulant for a patient with cancer, considering the clinical scenario.